Profile data is unavailable for this security.
About the company
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
- Revenue in CHF (TTM)1.27bn
- Net income in CHF112.06m
- Incorporated1904
- Employees3.93k
- LocationSiegfried Holding AGUntere Bruehlstrasse 4ZOFINGEN 4800SwitzerlandCHE
- Phone+41 627461111
- Fax+41 627461102
- Websitehttps://www.siegfried.ch/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals Ltd | 1.26bn | -203.15m | 4.26bn | 15.56k | -- | 5.07 | -- | 3.37 | -67.28 | -53.21 | 418.40 | 278.11 | 0.7004 | 1.81 | 4.28 | -- | -10.86 | 1.02 | -15.92 | 1.43 | 62.64 | 61.27 | -15.50 | 1.43 | 0.8447 | 1.19 | 0.1356 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
| Avidity Biosciences Inc | 9.71m | -204.35m | 4.43bn | 253.00 | -- | 5.37 | -- | 455.83 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Apellis Pharmaceuticals Inc | 468.31m | -372.88m | 4.46bn | 702.00 | -- | 18.71 | -- | 9.53 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -38.72 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Rohto Pharmaceutical Co Ltd | 1.53bn | 174.57m | 4.51bn | 7.26k | 25.01 | 3.13 | 19.93 | 2.95 | 135.21 | 135.21 | 1,183.75 | 1,079.72 | 0.8259 | 2.59 | 4.17 | 37,310,920.00 | 9.57 | 8.54 | 13.02 | 11.79 | 58.07 | 58.59 | 11.59 | 10.30 | 1.93 | -- | 0.0614 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 1.98bn | 466.65m | 4.53bn | 11.60k | 9.59 | 1.51 | 7.60 | 2.28 | 1,020.54 | 1,020.53 | 4,335.98 | 6,494.05 | 0.5724 | 1.46 | 4.05 | 68,856,070.00 | 13.62 | 11.64 | 15.34 | 13.28 | 67.11 | 58.18 | 23.80 | 18.93 | 3.08 | -- | 0.0153 | 39.94 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.94 |
| Siegfried Holding AG | 1.27bn | 112.06m | 4.54bn | 3.93k | 38.28 | 5.09 | 23.40 | 3.57 | 26.28 | 26.28 | 298.23 | 197.49 | 0.6958 | 2.27 | 3.14 | 323,288.60 | 6.17 | 6.51 | 7.67 | 7.98 | 25.20 | 23.24 | 8.86 | 9.06 | 1.39 | 7.93 | 0.3468 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
| Laboratorios Farmaceuticos ROVI SA | 758.74m | 134.24m | 4.56bn | 2.11k | 33.29 | 8.65 | 29.33 | 6.01 | 2.60 | 2.60 | 14.74 | 10.03 | 0.9364 | 0.9838 | 5.34 | 369,045.00 | 16.56 | 18.90 | 22.75 | 25.58 | 58.01 | 59.82 | 17.69 | 20.13 | 0.771 | 812.80 | 0.135 | 34.37 | 1.44 | 22.30 | -14.69 | 56.93 | 15.84 | 69.11 |
| GlaxoSmithKline Pharmaceuticals Limited | 369.46m | 63.11m | 4.73bn | 3.21k | 74.98 | 24.88 | 67.05 | 12.81 | 34.82 | 34.82 | 203.88 | 104.93 | 1.00 | 2.71 | 16.67 | 10,755,860.00 | 17.14 | 11.01 | 29.26 | 17.88 | 61.36 | 55.77 | 17.08 | 12.25 | 1.49 | 466.45 | 0.0104 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Hikma Pharmaceuticals Plc | 2.57bn | 169.81m | 4.76bn | 8.97k | 28.06 | 2.41 | 13.90 | 1.85 | 0.6595 | 0.6595 | 9.97 | 7.67 | 0.6284 | 1.76 | 3.67 | 247,297.50 | 4.20 | 8.19 | 5.72 | 11.30 | 48.94 | 50.29 | 6.68 | 13.77 | 0.9029 | 7.68 | 0.3503 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
| Krka d.d. Novo Mesto | 1.79bn | 315.37m | 4.77bn | 11.80k | 14.26 | 2.04 | 11.50 | 2.67 | 10.48 | 10.48 | 59.36 | 73.17 | 0.6528 | 1.37 | 3.57 | 157,225.70 | 11.51 | 12.64 | 13.68 | 15.12 | 55.99 | 57.29 | 17.64 | 18.71 | 2.88 | 66.70 | 0.0056 | 59.21 | 5.18 | 6.28 | -13.58 | 12.45 | 8.35 | 18.57 |
| Organon & Co | 5.67bn | 935.60m | 4.78bn | 10.00k | 5.10 | 110.92 | 4.15 | 0.8432 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| BridgeBio Pharma Inc | 195.34m | -480.99m | 4.89bn | 550.00 | -- | -- | -- | 25.04 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Financiere de Tubize SA | 0.00 | 85.85m | 4.91bn | -- | 57.16 | 2.80 | 57.16 | -- | 1.98 | 1.98 | 0.00 | 40.36 | -- | -- | -- | -- | -- | 7.04 | -- | 7.24 | -- | -- | -- | 145.70 | -- | -- | 0.0422 | 20.94 | -- | -- | 3.50 | -20.93 | -- | 11.61 |
Data as of Jul 17 2024. Currency figures normalised to Siegfried Holding AG's reporting currency: Swiss Franc CHF
22.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Jul 2024 | 156.54k | 3.47% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 142.28k | 3.15% |
| BlackRock Fund Advisorsas of 15 May 2024 | 133.67k | 2.96% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2023 | 132.98k | 2.95% |
| Credit Suisse Asset Management (Schweiz) AGas of 19 Feb 2024 | 129.57k | 2.87% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 108.46k | 2.40% |
| UBS Asset Management Switzerland AGas of 02 Jul 2024 | 88.14k | 1.95% |
| Brock Milton Capital ABas of 12 Jul 2024 | 46.29k | 1.03% |
| AXA Investment Managers (Paris) SAas of 28 Jun 2024 | 32.79k | 0.73% |
| Templeton Investment Counsel LLCas of 31 May 2024 | 28.74k | 0.64% |
More ▼
Data from 31 Dec 2023 - 12 Jul 2024Source: FactSet Research Systems Inc.
